Concluding that systemic FHR-3 levels were not exceedingly altered in AMD patients, we focused further on the local presence of FHR-3 to decipher the role of cfhr3/cfhr1 gene deletion in this disease. This evidence concerns the gene CFHR3 and age-related macular degeneration.